CY-09

CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation[1].

Product Specifications

CAS Number

[1073612-91-5]

UNSPSC

12352005

Hazard Statement

H302

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/CY-09.html

Purity

99.58

Solubility

DMSO : ≥ 150 mg/mL|H2O : < 0.1 mg/mL

Smiles

OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O

Molecular Formula

C19H12F3NO3S2

Molecular Weight

423.43

Precautions

H302

References & Citations

[1]Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214 (11) :3219-3238.